Regentis Biomaterials Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	6.64	0.71
Research & Development	0.33	-1.64
Total Operating Expenses	6.97	-0.93
Operating Income	-6.97	0.93
Total Non-Operating Income (Expense)	-6.68	3.87
Pretax Income	-13.65	4.8
Net Income	-13.65	4.8
Net Income to Common	-13.65	4.8
Shares Outstanding (Basic)	1	3
Shares Outstanding (Diluted)	1	3
Shares Change (YoY)	-79.51%	-
EPS (Basic)	-24.16	1.72
EPS (Diluted)	-24.16	1.72
Shares Outstanding	5.18	-
EBITDA	-6.97	0.93
EBIT	-6.97	0.93

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q